In vitro and in vivo evaluations of the activities of lauric acid monoester formulations against Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3187-3191

  Rouse, Mark S ^a   Rotger, Margalida ^a   Piper, Kerryl E ^a   Steckelberg, James M ^a   Scholz, Matthew ^b   Andrews, Jeffrey ^b   Patel, Robin ^a  

^a Mayo Clinic   (United States)

^b 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTROBAN NASAL; LAURIC ACID; PSEUDOMONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CARRIER; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; ERADICATION THERAPY; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NASOPHARYNX; NONHUMAN; OINTMENT; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARRIER STATE; DISEASE MODELS, ANIMAL; ESTERS; HUMANS; LAURIC ACIDS; METHICILLIN; METHICILLIN RESISTANCE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; NASOPHARYNX; OINTMENTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 23044506569     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3187-3191.2005     Document Type: Article

References (46)

1. Annigeri, R., J. Conly, S. Vas, H. Dedier, K. P. Prakashan, J. M. Bargman, V. Jassal, and D. Oreopoulos. 2001. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit. Dial. Int. 21:554-559.
2. Antonio, M., N. McFerran, and M. J. Pallen. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:438-442.
3. Baird, D., and J. Coia. 1987 Mupirocin-resistant Staphylococcus aureus. Lancet ii:387-388.
4. Bergsson, G., J. Arnfinnsson, S. M. Karlsson, O. Steingrimsson, and H. Thormar. 1998. In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides. Antimicrob. Agents Chemother. 42:2290-2294.
5. Bergsson, G., J. Arnfinnsson, O. Steingrimsson, and H. Thormar. 2001. In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob. Agents Chemother. 45:3209-3212.
6. Bergsson, G., J. Arnfinnsson, O. Steingrimsson, and H. Thormar. 2001. Killing of gram-positive cocci by fatty acids and monoglycerides. APMIS 109:670-678.
7. Bergsson, G., O. Steingrimsson, and H. Thormar. 2002. Bactericidal effects of fatty acids and monoglycerides on Helicobacter pylori. Int. J. Antimicrob. Agents 20:258-262.
8. Bergsson, G., O. Steingrimsson, and H. Thormar. 1999. In vitro susceptibilities of Neisseria gonorrhoeae to fatty acids and monoglycerides. Antimicrob. Agents Chemother. 43:2790-2792.
9. Boyce, J. M. 2001. MRSA patients: proven methods to treat colonization and infection. J. Hosp. Infect. 48(Suppl. A):S9-S14.
10. Chang, F. Y., N. Singh, T. Gayowski, S. D. Drenning, M. M. Wagener, and I. R. Marino. 1998. Staphylococcus aureus nasal colonization and association with infections in liver transplant recipients. Transplantation 65:1169-1172.
11. Clinical and Laboratory Standards Institute. 2003. Methods for dilution, antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, Pa.
12. Conley, A. J., and J. J. Kabara. 1973. Antimicrobial action of esters of polyhydric alcohols. Antimicrob. Agents Chemother. 4:501-506.
13. Cookson, B. D. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 41:11-18.
14. Decousser, J. W., P. Pina, J. C. Ghnassia, J. P. Bedos, and P. Y. Allouch. 2003. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. Eur. J. Clin. Microbiol. Infect. Dis. 22:318-319.
15. Fernandez-Guerrero, M., M. Rouse, N. Henry, and W. Wilson. 1988. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 32:747-751.
16. Food and Drug Administration. 1997. Substances generally recognized as safe; proposed rule (21 CFR 172.860). Food and Drug Administration, Washington, D.C.
17. Fuchs, P. C., R. N. Jones, and A. L. Barry. 1990. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J. Clin. Microbiol. 28:608-609.
18. Harbarth, S., S. Dharan, N. Liassine, P. Herrault, R. Auckenthaler, and D. Pittet. 1999. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1412-1416.
19. Hodgson, J. E., S. P. Curnock, K. G. Dyke, R. Morris, D. R. Sylvester, and M. S. Gross. 1994. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob. Agents Chemother. 38:1205-1208.
20. Holland, K. T., D. Taylor, and A. M. Farrell. 1994. The effect of glycerol monolaurate on growth of, and production of toxic shock syndrome toxin-1 and lipase by, Staphylococcus aureus. J. Antimicrob. Chemother. 33:41-55.
21. Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2004. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J. Antimicrob. Chemother. 53:102-104.
22. Kabara, J. J., D. M. Swieczkowski, A. J. Conley, and J. P. Truant. 1972. Fatty acids and derivatives as antimicrobial agents. Antimicrob. Agents Chemother. 2:23-28.
23. Riser, K. B., J. M. Cantey-Kiser, and J. C. Lee. 1999. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect. Immun. 6:5001-5006.
24. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.
25. Kokai-Kun, J. F., S. M. Walsh, T. Chanturiya, and J. J. Mond. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47:1589-1597.
26. Laupland, K. B., and J. M. Conly. 2003. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin. Infect. Dis. 37:933-938.
27. Miller, M. A., A. Dascal, J. Portnoy, and J. Mendelson. 1996. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect. Control Hosp. Epidemiol. 17:811-813.
28. Miller, S. J., R. Aly, H. R. Shinefeld, and P. M. Elias. 1988. In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. Arch. Dermatol. 124:209-215.
29. Mody, L., C. A. Kauffman, S. A. McNeil, A. T. Galecki, and S. F. Bradley. 2003. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37:1467-1474.
30. Neyts, J., T. Kristmundsdottir, E. De Clercq, and H. Thormar. 2000. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: impact on the search for vaginal microbicides. J. Med. Virol. 61:107-110.
31. Petinaki, E., I. Spiliopoulou, F. Kontos, M. Maniati, Z. Bersos, N. Stakias, H. Malamou-Lada, C. Koutsia-Carouzou, and A. N. Maniatis. 2004. Clonal dissemination of mupirocin-resistant staphylococci in Greek hospitals. J. Antimicrob. Chemother. 53:105-108.
32. Projan, S. J., S. Brown-Skrobot, P. M. Schlievert, F. Vandenesch, and R. P. Novick. 1994. Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol. 176:4204-4209.
33. Ruzin, A., and R. P. Novick. 1998. Glycerol monolaurate inhibits induction of vancomycin resistance in Enterococcus faecalis. J. Bacteriol. 180:182-185.
34. Schlievert, P. M., J. R. Deringer, M. H. Kim, S. J. Projan, and R. P. Novick. 1992. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob. Agents Chemother. 36:626-631.
35. Tacconelli, E., Y. Carmeli, A. Aizer, G. Ferreira, M. G. Foreman, and E. M. C. D'Agata. 2003. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin. Infect. Dis. 37:1629-1638.
36. Thormar, H., G. Bergsson, E. Gunnarsson, G. Georgsson, M. Witvrouw, O. Steingrimsson, E. De Clercq, and T. Kristmundsdottir. 1999. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. Sex. Transm. Infect. 75:181-185.
37. Thormar, H., C. E. Isaacs, H. R. Brown, M. R. Barshalzky, and T. Pessolano. 1987. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob. Agents Chemother. 31:27-31.
38. Upton, A., S. Lang, and H. Heffernan. 2003. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J. Antimicrob. Chemother. 51:613-617.
39. Ved, H. S., E. Gustow, V. Mahadevan, and R. A. Pieringer. 1984. Dodecyl-glycerol. A new type of antibacterial agent which stimulates autolysin activity in Streptococcus faecium ATCC 9790. J. Biol. Chem. 259:8115-8121.
40. Ved, H. S., E. Gustow, and R. A. Pieringer. 1984. Inhibition of peptidoglycan synthesis of Streptococcus faecium ATCC 9790 and Streptococcus mutans BHT by the antibacterial agent dodecyl glycerol. Biosci. Rep. 4:659-664.
41. von Eiff, C., K. Becker, K. Machka, H. Stammer, and G. Peters. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:11-16.
42. Walker, E. S., J. E. Vasquez, H. Bullock, and F. A. Sarubbi. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect. Control Hosp. Epidemiol. 24:342-346.
43. Watanabe, H., H. Masaki, N. Asoh, K. Watanabe, K. Oishi, S. Kobayashi, A. Sato, R. Sugita, and T. Nagatake. 2001. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 39:3775-3777.
44. Weinke, T., R. Schiller, F. J. Fehrenbach, and H. D. Pohle. 1992. Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus. Eur. J. Clin. Microbiol. Infect. Dis. 11:985-989.
45. Wilcox, M. H., J. Hall, H. Pike, P. A. Templeton, W. N. Fawley, P. Parnell, and P. Verity. 2003. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J. Hosp. Infect. 54:196-201.
46. Yun, H. J., S. W. Lee, G. M. Yoon, S. Y. Kim, S. Choi, Y. S. Lee, E. C. Choi, and S. Kim. 2003. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J. Antimicrob. Chemother. 51:619-623.